Chennai, India (CU)_ Recently, a new cocktail treatment based on a monoclonal antibody combination has been proposed as a viable option for individuals with Covid-related problems. In India, the central government has licensed its use, and hospitals have begun to employ it. Dr. D Nageshwar Reddy, chairman of AIG Hospitals Hyderabad, stated that the cocktail treatment can assist Covid-19 patients recover in as little as one week.
According to Reddy, AIG Hospitals has begun utilizing this medication for Covid-19 patients and is conducting a big trial to determine its efficiency against altered forms of the virus that causes the disease. Dr Reddy informed that the treatment is also being tested against the double mutant variant of the virus. He said, “Within one week, this treatment can help patients become RT-PCR negative. At AIG, we are doing a major study where we are looking at the efficacy of this treatment against the double mutant variant of the virus”.
Dr Reddy spoke about the scope of monoclonal antibodies. He also spoke about the effectiveness of the treatment against the COVID. He said, ”The real-world evidence of these monoclonal antibodies is yet to be established, but clinical studies published in peer-reviewed journals, including the New England Journal of Medicine, are encouraging as they have shown to reduce hospitalisation or death by over 70 per cent, including a drastic reduction in viral clearance”.
A mixture of two…
